에데사 바이오테크 (EDSA)

03:11 AM

Edesa Biotech (NASDAQ:EDSA) Given “Buy” Rating at HC Wainwright - Defense World

03:11 AM

Nov 03, 2025

HC Wainwright & Co. Reiterates Edesa Biotech (EDSA) Buy Recommendation - Nasdaq

Nov 03, 2025

Nov 03, 2025

Edesa Biotech (EDSA) Receives Reiterated 'Buy' Rating from HC Wa - GuruFocus

Nov 03, 2025

Nov 03, 2025

Is Edesa Biotech Inc. stock affected by interest rate hikesWeekly Volume Report & Risk Managed Investment Strategies - newser.com

Nov 03, 2025

Nov 03, 2025

Is Edesa Biotech Inc. still worth holding after the dipPortfolio Gains Report & Community Driven Trade Alerts - newser.com

Nov 03, 2025

Nov 02, 2025

Has Edesa Biotech Inc. found a price floorWeekly Trend Recap & Verified Stock Trade Ideas - newser.com

Nov 02, 2025

Nov 02, 2025

Best data tools to analyze Edesa Biotech Inc. stock2025 Trading Volume Trends & Expert Curated Trade Setup Alerts - newser.com

Nov 02, 2025

Oct 31, 2025

Edesa Biotech Inc. (EDSA) Stock Price | Live Quotes & Charts | NSC - StocksToTrade

Oct 31, 2025

Oct 31, 2025

Edesa Biotech, Inc. (EDSA) Stock Price, News, Quote & History - Yahoo! Finance Canada

Oct 31, 2025

Oct 31, 2025

Edesa Biotech to Participate in Key Industry Conferences - TipRanks

Oct 31, 2025

Oct 31, 2025

Edesa Biotech Announces Upcoming Conference Schedule - The Manila Times

Oct 31, 2025

Oct 31, 2025

Edesa Biotech (NASDAQ: EDSA) to attend BIO-Europe Vienna, LSX London in November 2025 - Stock Titan

Oct 31, 2025

Oct 31, 2025

Favourable Signals For Edesa Biotech: Numerous Insiders Acquired Stock - simplywall.st

Oct 31, 2025

Oct 31, 2025

Will Edesa Biotech Inc. stock benefit from sector rotationQuarterly Risk Review & Free Weekly Chart Analysis and Trade Guides - newser.com

Oct 31, 2025

Oct 29, 2025

Is Edesa Biotech Inc a good long term investmentMean Reversion Trades & Affordable Trading Portfolio - earlytimes.in

Oct 29, 2025

Oct 29, 2025

Edesa Biotech reports positive Phase III results for ARDS treatment - Yahoo

Oct 29, 2025

Oct 28, 2025

Edesa’s ARDS drug shows 25% reduction in death risk in phase 3 trial - Investing.com Canada

Oct 28, 2025

Oct 28, 2025

EDSA’s Market Surge: Time to Jump In? - StocksToTrade

Oct 28, 2025

Oct 28, 2025

Edesa Biotech (EDSA) FDA Approvals, PDUFA Dates & Drug Alerts 2025 - MarketBeat

Oct 28, 2025

Oct 28, 2025

Edesa’s ARDS drug shows 25% reduction in death risk in phase 3 trial By Investing.com - Investing.com South Africa

Oct 28, 2025

Oct 28, 2025

EDSA’s Performance: What’s Driving the Change? - timothysykes.com

Oct 28, 2025

Oct 28, 2025

Edesa Biotech Reports Positive Phase 3 Results For Paridiprubart In ARDS - Nasdaq

Oct 28, 2025

Oct 28, 2025

Edesa Biotech reports positive Phase 3 results for ARDS drug candidate - Investing.com Nigeria

Oct 28, 2025

Oct 28, 2025

Edesa Biotech Announces Positive Phase 3 Study Results - TipRanks

Oct 28, 2025

Oct 28, 2025

Edesa Biotech Announces Positive Phase 3 Results for ARDS Treatment - TradingView

Oct 28, 2025

Oct 28, 2025

Edesa Biotech Announces Positive Phase 3 Results for Paridiprubart in Treating Acute Respiratory Distress Syndrome, Showing Significant Reduction in Mortality - Quiver Quantitative

Oct 28, 2025

Oct 28, 2025

[8-K] Edesa Biotech, Inc. Reports Material Event | EDSA SEC FilingForm 8-K - Stock Titan

Oct 28, 2025

Oct 28, 2025

Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study - GlobeNewswire

Oct 28, 2025

Oct 27, 2025

Pigmentation Disorders Treatment Market Is Booming Worldwide 2025-2032 |Abbvie Inc., Edesa Biotech, Inc., Amgen - openPR.com

Oct 27, 2025